Harper Molly sold (to issuer) $116K of CPRX
Harper Molly sold (to issuer) 3,694 shares of CATALYST PHARMACEUTICALS, INC. (CPRX) at $31.50 ($0.12M total) on 2026-07-15.
How this was made
The 30-second read
Why it matters
The newest fact is the director’s sale to the issuer of 3,694 shares at $31.50, totaling $116,361, with no 10b5-1 plan stated.
Market read
Primarily a sentiment/positioning datapoint; no new Catalyst Pharmaceuticals business catalyst is provided.
What to watch
The transaction is coded as sale to issuer (often buyback participation) and the text shows holdings after transaction at 0 shares, which can be mechanically driven rather than a bearish signal.
Background
The article is an SEC Form 4 insider transaction disclosure for Catalyst Pharmaceuticals (CPRX).
Ticker impact
SEC Form 4 shows director Harper Molly sold 3,694 shares of Catalyst Pharmaceuticals to the issuer at $31.50 on 2026-07-15.
Likely minimal near-term impact; treat as routine insider liquidity unless follow-on filings indicate broader selling.
The filing is a Form 4 insider transaction with no 10b5-1 plan and no accompanying company guidance, deal, or regulatory update in the text.
Market effects
No sector read-across from a single director sale disclosure.
None indicated.
None indicated.
Counterpoint
If the sale is part of a broader pattern of director/insider selling, it could modestly pressure sentiment even without fundamentals changing.
Key entities
- issuerCATALYST PHARMACEUTICALS, INC.
Company whose director insider transaction is disclosed on SEC Form 4.
- insiderHarper Molly
Director who sold shares to the issuer; holdings after transaction are 0 shares.